The present invention generally relates to an aerosol formulation comprising formoterol, beclomethasone dipropionate and glycopyrronium bromide, said formulation being contained in a coated can, particularly useful for the use in a pressurised metered dose inhaler for the treatment of respiratory diseases.

In alternative embodiments, provided are pharmaceutical compositions comprising combinations of drugs, including products of manufacture and kits, and methods for using them, for treating, preventing, ameliorating, slowing the progress of, decreasing the severity of or preventing a coronavirus infection, or a COVID-19 or a 2019-nCoV (or so-called Wuhan coronavirus) infection, or an infection caused by a virus in the subfamily Orthocoronavirinae, or a virus in the family Coronaviridae, or a virus in the order Nidovirales. In alternative embodiments, combinations, or cocktails, of a drug or drugs as provided herein are administered either enterally, parenterally and/or by inhalation. In alternative embodiments, combinations, or cocktails, of drugs as provided herein are used to block intracellular metabolic pathways and prevent progression of the infection to clinical illness and death. In alternative embodiments, novel aerosol, spray or mist or powder formulations for inhalation are provided. In alternative embodiments, provided are therapeutic combinations of drugs or a drug, a pharmaceutical dosage form, a drug delivery device, or a product of manufacture, comprising: opaganib or YELIVA™, or opaganib or YELIVA™ and oral and/or inhaled chloroquine (or ARALEN™) chloroquine phosphate, chloroquine diphosphate and/or hydroxychloroquine (optionally, PLAQUENIL™), with or without azithromycin, wherein optionally each or all of the opaganib, the chloroquine (or ARALEN™), chloroquine phosphate, chloroquine diphosphate and/or hydroxychloroquine (optionally, PLAQUENIL™), and/or azithromycin, and others, are in or formulated as a formulation for inhalation, for example, formulated as an aerosol, spray, mist, liquid or powder.

Pre-connected analyte sensors are provided. A pre-connected analyte sensor includes a sensor carrier attached to an analyte sensor. The sensor carrier includes a substrate configured for mechanical coupling of the sensor to testing, calibration, or wearable equipment. The sensor carrier also includes conductive contacts for electrically coupling sensor electrodes to the testing, calibration, or wearable equipment.

Provided herein are intranasal fluid delivery devices and apparatus comprising a dispensing tip a shot chamber carrying a fluid, the shot chamber having a diaphragm at one end and a plunger at the other end, and an actuator connected to a push rod moveable toward the shot chamber.

A compact modular multifunctional inhalation device including a housing having an inlet port and an outlet port; a removable cartridge module adapted to seat within the housing, the cartridge including: a tray within the cartridge for holding a solid inhalant, a heating element mounted within the cartridge above and through the tray for heating the inhalant; and a removable modular electronic circuit adapted to seat within the housing to provide electrical current to the heating element. The heating element is a coil mounted within a chamber in thermal proximity to the solid inhalant. A quartz rod is mounted within the coil. A plunger is mounted within the cartridge to translate therein and compact the solid inhalant. In an alternative embodiment, dual channels and outlet ports are mounted in communication with an inlet port. In another embodiment, the cartridge is a split chamber cartridge with a split plunger mounted therein.

A pressurized metered-dose inhaler requires good synchronization between the activation of the inhaler and the inspiration by the patient. Processing is carried out on the video frames filming the patient to qualify the actuation of the pressurized metered-dose inhaler according to two criteria: regarding the pressing by the patient's actuating fingers on a trigger member of the inhaler and regarding the actual compression of the inhaler. Processing of an audio signal recording the patient at the same time is also carried out to detect an inhalation by the patient. A temporal correlation of the probabilities obtained as results then makes it possible to qualify the synchronization between the actuation of the inhaler by the patient and the latter's inspiration, and thereby indicate a proper use or improper use of the inhaler.

The invention provides an inhalation device system for the in-halative administration of a medically active liquid in nebulized form, the system comprising an inhalation device and an exchangeable reservoir for holding the medically active liquid, wherein the inhalation device comprises - a housing having a receiving unit, the receiving unit having a connection unit adapted to releasably and fluidically connect to a connection port of the exchangeable reservoir, the receiving unit being adapted to receive and fluidically connect to the exchangeable reservoir; - a nozzle for nebulization of the medically active liquid; and - a pumping unit arranged within the housing and adapted to be fluidically connected to the reservoir (via the connection unit of the receiving unit) and to the nozzle and being adapted to convey (pressurize, pump) the medically active liquid in a downstream direction from the reservoir to the nozzle.

The present invention relates to a novel propellant-gas-containing medicament composition based on tiotropium 1, processes for the preparation thereof and the use of such medicament compositions in the treatment of respiratory complaints.

An aerosol-generating device is provided, including a reservoir configured to hold a liquid; a release medium; and a heater, wherein the reservoir and the release medium are configured to transport liquid from the reservoir to the release medium, wherein the release medium and the heater are disposed in physical contact with each other, wherein the aerosol-generating device further includes a means for reversibly releasing the physical contact between the release medium and the heater to form a gap between the heater and the release medium, and wherein the aerosol-generating device is configured to activate the heater when the gap is formed between the heater and the release medium. A method for forming an aerosol by the aerosol-generating device is also provided.

A dry powder inhaler for delivering medicament from at least one medicament carrier having a plurality of spaced-apart medicament doses. The inhaler includes a housing having regions for accommodating unused and used portions of the medicament carrier, a mouthpiece component extending from the housing and through which a user is able to inhale, a dispensing mechanism arranged in the housing for moving a medicament dose of the medicament carrier to the dispensing position, and a mouthpiece cover being rotatably connected to the housing for sequential movement about a rotation axis from a first position in which the mouthpiece component is completely covered to a second position in which the mouthpiece component is completely covered, and from the second position to a third position in which the mouthpiece component is completely uncovered, the second position being between the first and third positions.